loading...| Preferred Name |
mirabegron |
|
| Synonyms |
YM178 Myrbetriq 2-(2-aminothiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl] acetamide Betanis 4-thiazoleacetamide, 2-amino-N-(4-(2-(((2R)-2-hydroxy-2-phenylethyl)amino)ethyl)phenyl) YM 178 |
|
| Definitions |
An orally bioavailable agonist of the human beta-3 adrenergic receptor (ADRB3), with muscle relaxing, neuroprotective and potential antineoplastic activities. Upon oral administration, mirabegron binds to and activates ADRB3, which leads to smooth muscle relaxation. Mirabegron also restores sympathetic stimulation in mesenchymal stem cell (MSC) niches, inhibits JAK2-mutated hematopoietic stem cell (HSC) expansion and blocks the progression of myeloproliferative neoplasms (MPNs). Lack of sympathetic stimulation of the MSC and HSC niches is associated with the development of MPNs. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C90633" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C90633" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000767328 |
|
| altLabel |
YM178 Myrbetriq 2-(2-aminothiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl] acetamide Betanis 4-thiazoleacetamide, 2-amino-N-(4-(2-(((2R)-2-hydroxy-2-phenylethyl)amino)ethyl)phenyl) YM 178 |
|
| CAS Registry |
223673-61-8 |
|
| cui |
C3489691 C3485428 C1957299 C2983812 |
|
| DATE FIRST PUBLISHED |
2014-12-15 |
|
| Date last modified |
2015-02-06 |
|
| definition |
An orally bioavailable agonist of the human beta-3 adrenergic receptor (ADRB3), with muscle relaxing, neuroprotective and potential antineoplastic activities. Upon oral administration, mirabegron binds to and activates ADRB3, which leads to smooth muscle relaxation. Mirabegron also restores sympathetic stimulation in mesenchymal stem cell (MSC) niches, inhibits JAK2-mutated hematopoietic stem cell (HSC) expansion and blocks the progression of myeloproliferative neoplasms (MPNs). Lack of sympathetic stimulation of the MSC and HSC niches is associated with the development of MPNs. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C90633" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C90633" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C90633 |
|
| notation |
CDR0000767328 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
mirabegron |
|
| tui |
T109 T121 |